Thoracic Malignancies   

Questions discussed in this category


Is there data to guide treatment re: SBRT vs. concurrent chemoradiation vs. sequential therapy vs. systemic therapy alone? Does the nodal location imp...

Should staging and treatment decisions be made based on imaging alone?

How would you approach a patient who is receiving chemoRT but has confirmed COVID-19 with minor symptoms, as breaking treatment for 2 weeks quarantine...

If so, for how long would you expect this increased susceptibility to last? Our medical oncologists often tell patients that their lymphocyte counts m...

Also, how would you handle immune modulators for rheumatoid arthritis during their treatment?

Many commercial testing assays report on EGFR gene amplification in addition to the known sensitizing mutations. Are there any data that this can be u...

Would you treat with chemotherapy (carboplatin/etoposide) vs anti-pd-1 monotherapy vs combination chemoimmunotherapy vs supportive care?

If a non-contrast CT is not performed at CT simulation or otherwise not useable, can you plan on the contrast CT or must you re-simulate for cancers n...

NCCN recommends achieving margins of 2.0cm or at least the size of the lesion, but assuming the patient did not have adequate lung function for lobect...

Would you consider this standard in asymptomatic patients for workup and treatment planning? Or do you reserve MRI for symptomatic patients only?

Most trials establishing CRT as standard of care for IIIB NSCLC excluded patients with separate ipsilateral lung nodules given that they were categori...

The recent NELSON trial evaluates screening in a slightly different population than the USPSTF/NLST criteria. Which will you follow?

Is your approach to simply calculate the EQD2 for specific lung constraints from the prior SBRT and add to the current plan to use cumulative standard...

If a patient was administered GM-CSF during concurrent chemoRT, would this be an indication to hold RT, regardless of cell counts (e.g. based on Bunn ...

Keynote 407 recently published data on pembrolizumab +/- chemo for metastatic squamous cell lung cancer.  The confidence interval for the group w...

Are there specific mutations or co-mutations were you would consider use of this agent? 

Do you worry about chest wall necrosis? Is surgery preferable? Does the previous RT affect your dose and fractionation? I am seeing more patients with...

Especially if you don't have trials available at the moment. Would you try off-label erdafitinib (given recent data on bladder cancer) or 2nd line ge...

What dose constraints would you prioritize for the esophagus, given that a long segment of esophagus will be in PTV?

Do the results of the unplanned subset analysis of the PACIFIC trial showing no OS benefit in this population lean you away from consolidation?

How (if at all) would you modify your target volume if the hemorrhage was present on immediate post-biopsy CT, but resorbed by time of CT sim? What ab...

Our medical oncology team wants to give a patient Vitamin B12 and Folate 1 week before chemo- do we need to push back the RT start date to start both ...

Does tumor location play a role (central vs peripheral) in making the decision?  The question stems from an oral presentation at ASTRO 2014 inves...

How do you approach this given the limited # of patients this applies to?  Checkmate 017 and 057 only had 5-7% of patients still on nivolumab at ...

In patients who have a mixed response or progression and are poor candidates for other systemic agents, would you consider consolidating the chest? Wo...

In the absence of a frontline clinical trial, would you treat with carboplatin+pemetrexed+pembrolizumab or consider IMPOWER 150 or other?

Are the other options of chemotherapy that can be used instead of platinum based doublets, including with paclitaxel? 

Is there evidence that supports/refutes the safety of concurrent use?

Would you consider first line treatment with somatostatin analog or Lu 177 dotatate? Is observation an option for asymptomatic patients?

Would you give a more definitive dose (e.g. 60 Gy/30 fractions) or follow the CREST trial (30 Gy/10 fractions)?

In a patient with lung cancer with both NSCLC and SCLC components, would you offer carbo/pem/pembro or carbo/etoposide/atezolizumab? Or any other alte...

Would you suspect progressive disease v. radiation necrosis vs optic neuritis due to immunotherapy. Eyes were within radiation field 8 months ago.&nbs...

The NCCN guidelines regard  MET exon 14 skip mutation   as an emerging biomarker but no formal recommendation to start crizotinib. If high P...

Are there any biomarkers that would affect your decision for first line PD-1 therapy (including but not limited to STK11)? 

1st-line pembrolizumab is supposed to be used AFTER failure of appropriate targeted agents in this setting, but would you consider the reverse sequenc...

For instance, not chronic autoimmune diseases (eg RA, IBD) that may relapse/remit but events like Guillan Barre syndrome that is not likely to recur b...

Given the potential high risk of developing pneumonitis with TKI post checkpoint inhibitor, do you avoid TKIs and try a different regimen (ex carbo/pa...

One example of this scenario would be a patient receiving consolidative durvalumab after chemoRT for stage III NSCLC who develops a new peripheral lun...

I've been trained to treat the larger lesion, re-stage, and then treat the other lesion if there are no new lesions (to rule out the possibility of me...

With the recent finding of benefit of pembrolizumab and SBRT (PMID: 31294749), would you consider "adjuvant" pembrolizumab for PDL1 positive patients?...

Do you recommend or make any modifications in the PACIFIC regimen for patients > 75 years of age?

Would you reserve TKI for after standard of care chemotherapy and immunotherapy or consider earlier line of treatment?

Much of this approach was designed with cytotoxic chemotherapy in mind -- wait "x" cycles, assess response, deliver radiation after chemotherapy. How ...

How do you surveil or decide to biopsy and treat these additional lesions? Are there certain size, growth rate, or imaging criteria that are usef...

In clinical practice, consolidation chemotherapy is sometimes used, though this was not implemented in the PACIFIC trial. https://www.ncbi.nlm.nih.go...

Would this approach be different for a patient treated with tri-modality therapy (ie neoadjuvant chemoradiation followed by resection)?

Given the prior results of Keynote 189, how do you plan to utilize the data from Keynote 042 with pembrolizumab monotherapy?  

Or do you reserve in case of oligo-progression or progressive/symptomatic disease? 

How do you prescribe a steroid taper? If it is grade 2, would you keep them on low dose prednisone while continuing? When do you feel comfortable re-c...

What are the major factors that impact your decision? If you opt for surgery, what factors impact your decision to offer RT preoperatively vs. postope...

Is 30Gy/10fx from the CREST trial standard? Do you ever use a more/less protracted fractionation? Does a malignant pleural effusion at diagnosis affec...

Rate of pneumonitis was low in the PACIFIC trial but does it mirror the real world setting? We are seeing increased pneumonitis in our practice.

For example in a patient with a good performance status and a biologically favorable cancer (ER+ breast cancer, EGFR+ NSCLC, or prostate cancer), are ...

Do you feel it is important to start durvalumab within 14 days of completing cCRT?  What real life challenges do you face in doing so and wh...

Do you consider size > 2cm, visceral pleural invasion or vascular invasion as indications for cisplatin-based chemotherapy? 

Medical inoperability is clearly defined, anatomical resectability is also pretty much clear (invasion of trachea/carina/esophagus, etc). But what abo...

Would you treat to the GEJ regardless of whether the positive node was identified in the upper portion of station 8? Do surgeons routinely dissect to ...

NCCN guidelines recommend adjuvant chemotherapy for patients with stage 2 or 3 R0 resected NSCLC including 4 cycles of platinum based chemotherapy, bu...

Do you consider specific pre-medications, an alternate checkpoint inhibitor, or abandon ICI altogether? 

Do you routinely offer post-operative adjuvant radiation in addition to chemotherapy? 

Retrospective studies (PMID: 29935305, PMID: 30125216) have shown a correlation between poorer outcome and baseline steroid use in patients treat...

If you are using a standard 30/10 fractionation, is there a benefit to keeping chemo on board for radio-sensitization?

Would you treated with local therapies (RFA or SRS) and continue pembrolizumab or would you move to second line treatment?

If clinically node negative, would you add elective nodal radiation?Does it depend on location (upper vs. lower trachea)?

Retrospective data suggest clinically significant disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung canc...

Do you use BID treatments toward the end? Do you add additional daily treatments to exceed the prescription dose? Would you alter systemic t...

First line pembrolizumab is only approved after progression on TKI - but would you ever offer chemo-immunotherapy prior to target therapy? 

Is the timing of progression (in relation to chemoradiation) a factor, and is there any role for repeat PD-L1 testing at the time of progression?

Are pre-treatment PFTs actually correlated with treatment-related toxicity? If no absolute cutoff, do you have an ideal lower limit for PFTs...

The FDA has approved the new dosing schedule of Nivolumab 480 mg every 4 weeks for multiple disease sites (melanoma, RCC, urothelial carcinoma, SCC of...

The EGFR subgroup appeared not have benefited as much as other patients in the publication. However, recently it was reported that the PACIFIC study m...

Is there any correlation with dose in the area of the phrenic nerve and development of referred shoulder pain and/or diaphragm paralysis?

Is there an established benefit for this? For instance if your patient has cardiac calcifications on imaging but no history of cardiac disease are the...

If all other nodes were negative but the patient was pN2 due to a level 9 LN, what volume would you treatm? 

For example, would you modify your SBRT dose next to the azygous vein? While we talk frequently about OAR constraints for the great vessels, it seems ...

For the first treatment day (during combined chemo/XRT courses), is it ok to give XRT first then send the patient for chemo or should the chemo be giv...

I am treating a left lower lobe NSCLC and my PTV is so close to the spleen that a small portion of the spleen is getting significant dose.  I can...

If yes, do you recommend it be given concurrently with chemotherapy or sequentially? What is your target volume and dose?

Would you consider adding atezolizumab to a cisplatin/irinotecan regimen, or cisplatin instead of carboplatin?

As a for instance, a centrally located primary tumor with mediastinal adenopathy that results in a TE fistula? Currently we would recommend esophagea...

In a stable patient, do you perform standard chemoRT in 2 Gy fractions with IMRT for urgently start with a few high dose fractions (ex 4Gy/fx) and bri...

If there was a stage III adeno lung cancer and a contralateral SCC lung primary, what would be the best way to treat?

Would you consider treating 3-5mm lesions with SBRT or wait until they are a certain size? I am concerned I will not be able to see them adequately on...

Would you use a similar dose and fractionation as gastric MALT (30Gy in 1.5 Gy fractions)?

Would you recommend empiric diflucan? Would EGD be indicated? At what point would you consider hyperbaric oxygen?

No other site of metastatic disease. It is unclear if this situation should be managed as two separate primaries or metastatic disease.

What factors do you use to decide between weekly low-dose carboplatin and paclitaxel combination vs cisplatin based doublet, and do you routinelt...

This is a commonly used hypofractionated RT schedule in Canada, but the BED is lower than that for doses used in the US. If so, do you modify your dos...

What would you anticipate with regard to potential adrenal toxicity when the patient has only 1 functioning adrenal gland? There are no other sites of...

There is no primary and no distant disease seen on restaging PET. RTOG 0236 shows significant regional failure rate. Some have reported salv...

Does EGFR+ status influence your decision? What is the significance of this finding and its potential for progression? Is it simply occult disease con...

Do you recommend or withhold influenza and pneumonia vaccines while on treatment with checkpoint inhibitors?

I see the LungTECH trial dose constraints, but, they seem really conservative when you have something large and close the PBT resulting in use of 60 G...

How about for non-UIP vs UIP? Non-improvement of ILD with steroids? Specifically in O2-dependent patients? Does the volume of ILD sway your decision (...

Would an excellent KPS, LVSI+ or poorly differentiated histology change your decision? Would you base your decision on the ANITA trial where subset an...

Since the randomized phase II data from Gomez et al presented at ASTRO 2018 showed a survival benefit, is there concern about randomizing patients to ...

Does it factor into your decision making in the setting of restricted spirometry and normal lung volumes? Does this differ for SBRT v. chemoRT?

If a patient clearly has N1 disease with high SUV on PET, do you routinely recommend EBUS or mediastinoscopy to evaluate for N2 disease?

If there is no other evidence of metastatic disease, would you offer thoracic radiation? Either upfront with chemo or after initial system therapy if ...

The NCCN guidelines suggest surgery can be considered for up to T3N2 NSCLC after a period of induction chemotherapy/chemo-radiation without progressio...

What chemotherapy and radiation doses/fractionation would you use once the airway has been stabilized to provide reasonably safe and effective palliat...

Would your answer differ based on whether the patient is receiving concurrent chemotherapy? Are there other factors that would influence this decision...

Is this recommended in a certain subset of patients (EGFR positive or 1 metastasis only)? Or should we await maturation of the MD Anderson/Colorado/On...

There seem to be a lot of different fractionation schemes in the literature. Is there one that is most standard?

Do you prefer breath-hold techniques (ABC, DIBH) or abdominal compression regardless of tumor motion? Or do you use a general threshold number of cc's...

Carbo/pemetrexed/pembrolizumab, carbo/pemtrexed without immunotherapy or second line immunotherapy (Nivo, Pem or atezolizumab)?

The Indiana report and RTOG published a "danger zone".  There was a catastrophic "case report" for 50 Gy in 5 fractions.  Are there alternat...

Prior to the PACIFIC trial, patients were treated with definitive chemo/rads. With local recurrence <1yr after chemorads and definitive treatment f...

For a Stage III NSCLC looking to do definitive chemoRT who required IVIG and high-dose prednisone for paraneoplastic myopathy (mimicking dermatomyosit...

 Ex. TP53, BRCA, T790M, or another? As of now, T790M mutation is one of the few de novo mutations found in treatment naïve patients  th...

The ALTA and ALEX trials showed better PFS with brigatinib v. crizotinib and alectinib v. crizotinib. How do you choose your first...

Would starting with chemotherapy be preferred in this situation and consider concurrent radiation, then switch over to Pembrolizumab once some control...

In a patient with a cavitated lesion with underlying chronic infection (identified as cocci) and SqCC, are there additional risks to SBRT? Should spec...

In patients with aberrant anatomy due to previous surgery with lung PTV overlapping the stomach, how much would you dose de-escalate? Even conventiona...

This has become standard practice at our institution for patients with a good performance status, with whole brain radiotherapy given after the comple...

There is no evidence of disease outside the lung on PET, and the patient is completely asymptomatic with negative EGFR, ALK, ROS1, and BRAF and a PD-L...

If so, what constraint is most clinically relevant? The EORTC LungTech trial (60Gy/8 fractions) does not specify a chest wall constraint. I have...

PD-L1 < 50% and no targetable mutations. Would you use carbo/pemetrexed/pembrolizumab or Nivolumab or pembrolizumab?

For example, would a + vascular margin, extranodal extension of N1 disease, translobar disease, or high risk histologies (large cell neuroendocrine, s...

Would you repeat PET or is it adequate to change to CT surveillance? Although surveillance PET/CT is not recommended by NCCN guidelines, these are oft...

Would you treat with localized therapy with chemoradiation or SBRT or consider ROS-1 directed therapies? 

Do you discuss this at the first consultation? Is there strong evidence to suggest that risks are significantly increased compared to upfront lobectom...

Would you use the same schedule as early stage NSCLC primary?

The current NCCN guidelines reserves radiation for patients who are not resectable after induction chemotherapy. Does it make sense to offer concurren...

Lung primary is inaccessible for biopsy and metastatic sites are only 2 small bone lesions. In a non-smoker, a driver mutation is suspected but would ...

Would your choice of treatment change if the same patient was T790M negative and osimertinib was given as a first-line therapy?

Do you prefer carboplatin-paclitaxel-bevacizumab, carboplatin-pemetrexed-pembrolizumab, or chemotherapy alone?

Is local control worse for SBRT when the tumor is invading into the bone (rib)?

Would anyone consider elective mediastinal XRT to 45-50Gy then boost involved LN to 60-66? Or treat involved lymph node only?  The patient will r...

Does the more recent NEJ026 trial describing benefit from Bevacizumab plus Erlotinib over Erlotinib alone in patients with EGFR driver mutations ...

Certainly ovarian cancer will respond to carboplatin and paclitaxel and it sounds like a reasonable chemotherapy to give to a stage IV NSCLC, however ...

If there are 3 negative scans, do you continue annual screening?

A recent phase III trial published in JCO describes the NVALT-11/DLCRG-02 study, evaluating PCI vs observation in patients with stage III NSCLC s/p co...

Specifically in O2-dependent patients? Have any dose/fractionation regimens been shown to reduce the risk of pneumonitis in this population?

Specifically, would carbo-taxol-bev-atezo (IMpower 150) be an attractive option given the activity of bev-atezo in sarcomatoid PDL1+ metastatic RCC (I...

I recently saw a patient who had been treated with concurrent pembrolizumab-RT elsewhere. Is this an acceptable practice outside the setting of a clin...

For the Impower 150 trial, is there data reported on PFS and OS for ABCP vs ACP (atezolizumab/bevacizumab/carboplatin/paclitaxel vs atezolizumab/carbo...

Or would you wait to start coincident with the start of cycle 2? If a shorter time from the start of any therapy to the end of radiation (SER) is sign...

Can SRS or whole brain radiotherapy be reserved for progression in these young, healthy patients?

Are there any data to support a specific TKI therapy for non-T90M exon 20 mutations/insertions? 

If so, what fields do you irradiate? The initially involved nodal regions? If not, do you consolidate at any point in the future (ie after a loca...

For example, a NSCLC of the LLL abutting and potentially involving the adventitia of the descending aorta?

For a patient with a new contralateral primary or recurrence and previous pneumonectomy, what lung constraints do you prioritize (ex mean lung dose, V...

By the definition this would be M1 disease, but would definitive treatment be appropriate? Is there clear data that a single pleural nodule has no cha...

Would you consider "aggressive" concurrent chemoradiation followed by SRS to the CNS lesion and possible consolidative immunotherpay (the PACIFIC...

In elderly patients (>70-75) with a good performance status, does the risk of neurocognitive decline outweigh the benefit of PCI?

Under what circumstances would you treat elective nodal regions? Would you consider treating the ipsilateral hilum if it was not PET avid?

Would you consider MS an absolute contraindication to this treatment?

In a patient with newly diagnosed small cell lung cancer with disease limited only to the thorax would you treat with definitive chemoRT in the presen...

In a patient with pain that does not respond well to narcotics what would be your treatment approach?  Is there any data that suggests patients c...

Given the results of Keynote 189, is there any benefit of chemotherapy+pembrolizumab in specific subsets of patients in the first line setting?

If so, would you recommend adjuvant chemotherapy and PCI after?

The NCCN guidelines for post-operative RT for Stage I lung cancer with positive margins is PORT to 54-60 Gy (in event re-resection is not feasible). I...

Do you electively treat the tracheobronchial tree? Or a certain length of the trachea and bronchus? Does the volume and dose depend on location (...

In the absence of clinical trial, is there are role for dose-escalating alectinib, or would you consider brigatinib or chemotherapy?

When would you favor delivering local therapy (e.g. SBRT) prior to systemic therapy?

These patients have been largely excluded from these trials.  What if the infection is well controlled?

Do you increase dosage of the TKI or switch to a different generation TKI?  How does your answer differ for EGFR vs. ALK, and for discerete brain...

If you are considering chemotherapy and radiation in the definitive, postoperative, or nodal failure scenarios, would you prefer sequential treat...

Assuming it is clinically indicated, would a checkpoint inhibitor be efficacious in a patient who has a concurrent autoimmune illness (PMR/TA) and is ...

Would you ever considering re-starting immunotherapy before completing the taper? According to the new guildelines on managing immunotherapy related ...

If so, 50 Gy / 5 fx? 7.5 Gy / 8 fx? If so what dose constraints would you use to help determine fractionation?

What are some guidelines or principles that you use to recommend adjuvant radiation after complete resections of sarcoma? 

If you treat pre-chemotherapy volumes, is there a benefit to induction chemotherapy even in bulky disease. If so, how do you define disease that ...

What factors influence your decision (R1 v. R2 resection? T stage?) If sequential, do you typically prefer radiation before or after chemotherapy?

Is there a role for SBRT to the primary site? Is it required to treat the ipsilateral hilum if no adenopathy was seen on EBUS or PET?

Given the lepidic growth pattern, do you use similar margins as with frankly invasive lung tumors? Are there any challenges localizing the target with...

When treating lung tumors abutting the visceral pleura/chest wall with SBRT, chest wall or rib pain sometimes occurs. In these cases, I try to avoid i...

Are two negative pleurocentesis' adequate to conclude that the patient does not have metastatic disease? Do you routinely recommend VATS and pleural b...

Would you treat if there is active infection?  How much improvement would you expect?

Would you treat if the patient is asymptomatic?  If you do treat, what dose/fractionation would you use?

Is a pleural effusion not oligometastatic by definition? The best evidence for consolidative RT was the MD Anderson/U Colorado/Western Ontario phase I...

Can T790M mutation develop within this early time frame, or are these perhaps patients who may benefit from switch to chemotherapy?

Or do you recommend treatment with systemic therapy alone, as this represents Stage IV disease?

Any special dosing considerations or can you approach this like any other small peripheral NSCLC?

Are you using ctDNA blood tests for targetable mutations at the time of diagnosis, at the time of disease progression, or not at all?

Are there any rules you follow? Do you shrink target volumes if you notice a significant response (via CBCT) in a bulky lung tumor with fractionated r...

How does this approach change with mediastinal lymph node involvement? What are the indications for definitive or adjuvant radiotherapy +/- chemothera...

Which imaging studies do you perform and what is the timing after treatment?

What is the best evidence for what dose to use? When would you give it in relation to the checkpoint inhibitors? Which metastatic sites do you choose ...

How would you approach the lung constraints in a patient that received definitive RT doses >2 years ago and develops a new primary amenable to SBRT...

Now that RTOG 0915 shows 5 year data with no difference in OS, DFS, and toxicity, should single tx be routinely offered? Are there specific  pati...

When is SBRT appropriate? Do you approach dose and fractionation differently in this setting?ƒ

How do you select between the available treatment options (gemcitabine, docetaxel, paclitaxel, nab-paclitaxel) in combination with platinum?  Up...

If patients do recur, do you perform these tests on the initial surgical specimen or on tissue from a fresh biopsy (or both?)

Would a large number of peribronchial nodes but negative nodes at the hilum and mediastinum (LN stations 7-10) affect decision making or volumes? What...

When there is biopsy proven mediastinal disease, do you offer definitive chemoradiation and monitor, or do you try to prove the presence/absence ...

When patients have a single site of progression while on systemic therapy is it reasonable to consider stereotactic and/or conventional radiation to d...

Has the recent FDA approval of dabrafenib/trametinib changed your practice?

Are there specific conformality parameters you prioritize (105% dose volume outside of PTV, conformality index, ratio of 50% isodose volume to PTV, an...

Although elective nodal irradiation is not standard, what you treat lymph node stations that are adjacent to involved lymph nodes? For example, i...

Can the ipsilateral supraclavicular field and bilateral hilar nodes still be limited stage? 

Similarly, would SBRT be an option for a small central persistent node? What maximum total BED would you accept before no longer recommending addition...

Nivolumab/ipilimumab is an option listed within NCCN guidelines for this patient population based on the early results of the Checkmate 032 trial. Do ...

Given that prophylactic cranial irradiation (PCI) has been shown to decrease the incidence of symptomatic brain metastases in patients with extensive ...

Have the results of LUX-Lung 7 changed your routine practice? Are there promising up-front clinical trials that these patients may benefit from?

Do you incoprate Ki67% or mitotic rate into your treatment decision, and is there any use for somatostatin based imaging such as octreoscan or gallium...

After sublobar resection and well dissected mediastinum, would you soley focus on the area of the positive margin or would you include ipsilateral hil...

Have you ever seen toxicity related to diaphragm dose with conventional fractionation?  

Should we be routinely sequencing ALK to select an ALK inhibitor with the appropriate efficacy, matched to resistance patterns?

Does the site of oligometastasis matter (ex. brain v bone)? In this trial https://www.ncbi.nlm.nih.gov/pubmed/27789196 20% of patients were ...

What is the average healing time? What medications and/or procedures do you recommend for pain control? Does management differ for those with chest wa...

Do you specify an isodose line to prescribe to? Do you ask for a percent hot, and if so do you specify what percent or volume of the GTV/ITV should re...

Do you use V5, V30 (as per Dess, JCO 2017)? V50 (Speirs, JTO 2017)?  Mean (Wang JCO 2017)? What is the most evidence based criteria? How do you b...

Is there any role for consolidative RT/CRT to the lung and mediastinum after initial chemo? What dose and fractionation would be most appropriate for ...

Would a postiive margin or extracapsular extension altar your recommendations? Does size play a role in your recommendation?

Under what clinical circumstances would you consider prescribing them?

For instance with isolated progression at one metastatic site, with all other disease stable and clinically doing well. 

How do the different assays compare when choosing a specific immunotherapy, and does this change for first vs second (or beyond) line of therapy?

How long do you typically wait before starting consolidation chemotherapy, and do you routinely perform re-staging scans prior to consolidation? 

For example, there is a retrospective series out of MD Anderson (Kim, Acta Oncologica 2008) wherein 37 patients with gastric cancer were treated with ...

What immunosuppressive agents are used and in what order?  Does your approach differ depending on the organ involved, e.g. colitis vs. pneumoniti...

In addition to addresing the brain met (surgery vs. SBRT), would you proceed with systemic "adjuvant" chemotherapy, or would you treat the patient as ...

There are varying reports in the literature which seem to suggest increased rates of Gr 4-5 pneumonitis in IPF patients.  How do you manage these...

 Is there any data to support this approach? If not, are there trials you are aware of looking at "rescuing" these patients with a different chec...

Does the extent/duration of systemic disease control (complete response vs. stable disease, for example) influence your decision?  What about whe...

What is the expected rate of pneumonitis with this approach? What dose/fractionation, and constraints would you use?

Does the risk of severe inflammation of the liver lead you to choose other therapies in in this population?  What about in patients with mild liv...

Additionally, would you give elective nodal coverage or just the postop bed?

What fractionation scheme would you use?  Would you give SBRT to a hilar tumor that has N1 nodal involvement adjacent to the tumor but can be enc...

If these are presumed to be immune-mediated (e.g. immune neutropenia or immune thrombocytopenia), do you treat with steroids?

The Phase III J-ALEX study and two phase II studies seem to suggest favorable intracranial response rates for alectinib. 

In the study published by Slotman et al (Lancet 2015), nearly all the patients in the thoracic RT arm started with PCI. For patients with gross diseas...

In my experience, it seems like the post-SBRT area of fibrosis is more than I would have otherwise expected with GGOs.  I have usually advised wa...

If PET/CT is unrevealing for a primary source, would you treat such a patient with platinum-etoposide or monitor closely until further disease progres...

What if there was a pT1aN0 invasive adenocarcinoma that was separate from the focus of adenocarcinoma in situ which resulted in the positive margin. &...

If so, what adjustments do you make? Does your recommendation change based upon how long the lobe has been collapsed and/or its presumed functionality...

Does recent data from the OAK study showing a survival benefit for atezolizumab over docetaxel even in non-smokers affect your decision making?  

For example, would you offer a patient SBRT with 3-4 lung SCC nodules? If so, how do you approach planning?

Our lung cancer screening program does not enroll anyone who has previously been deemed to be a nonsurgical candidate.  I see that there is no ev...

If not what radiation fractionation regimen is preferred for otherwise good KPS patient? 

Should surgery followed by adjuvant chemotherapy and radiation be considered for non-bulky single station N2 disease?

Since results of the phase III J-ALEX study were reported at ASCO 2016, do you try to obtain alectinib in the first-line setting instead of crizotinib...

Based on recently published data from CheckMate 032, do you now offer nivolumab to small cell patients who have progressed after first-line chemothera...

Would adjuvant chemotherapy suffice, or would you also consider RT in a patient with a PS of 0-1?  Would your recommendations change if it was N0...

If a biopsy carries a high risk of morbidity what interventions would you recommend for the local failure?

Does the type of autoimmune disease (ex IBD, rheumatoid arthritis, interstitial lung disease) matter?

The NCCN guidelines call for pathological mediastinal lymph node staging for all NSCLC except in solid tumors <1cm and non-solid lesions < ...

4cm has historically been used as the cutpoint for determining benefit from adjuvant chemotherapy in this population (Strauss et al, JCO 2008; Bu...

Although PD-1 inhibitors are now standard of care for second-line therapy of advanced NSCLC, there remains the question of which therapy is best to us...

Is it reasonable to dose escalate beyond 60 Gy if meeting all dosimetric criteria and with some room to spare? RTOG 0617 would suggest 60 Gy should be...

It seems like the RADIANT trial, finding an 18 month DFS benefit for adjuvant erlotinib, would favor this, but the study calls this "not statistically...

Following lung RT, I have rarely seen patients present with pneumonia-like symptoms of radiation pneumonitis. I'm more likely to see a patient with wo...

Is standard chemoradiation the standard of care or conventional fractionation dose-escalated (>60 Gy) radiotherapy without chemotherapy or some for...

What are some appropriate dose fractionations?  What about dose constraints for bronchial tree that previously got 70Gy?

As it is suggested for larger tumors treated with surgery, based on post hoc CALGB analysis?

The NCCN guidelines discourage the use of PET/CT surveillence but the recent analysis of RTOG 0235 found post-CRT PET uptake to be associated with wor...

Based on the European data published in the Lancet (http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2961085-0/abstract), are you s...

Do you treat the hilum and ipsilateral mediastinum?  Just the lymph node levels that were positive at surgery?  I have not found good guidel...

For example, should nivolumab be considered standard second-line therapy for adenocarcinoma patients?   Can it be considered for first-line thera...

In other words, if offered wedge or segmentectomy, should SBRT be preferred? Does size matter ie if the lesion is < 3 vs < 2 vs < 1 cm? Does ...

The BED10 for 50 Gy in 5 fractions is 100, which is significantly lower then the BED of the 54 Gy in 3 fractions regimen (151). Since the Kestin/Grill...

Our dosimetrists rarely meet the RTOG constraint using a non-coplanar technique, especially for very small lesions. I haven't been able to find a corr...

Does IFRT include only the involved lymph nodes + margin or the entire involved lymph node station as specified by the Michigan Atlas?

Are your constraints different than the standard constraints used for patients who have not had surgery?

I am aware that chemotherapy can obviate the need for RT in patients with SVC syndrome, but I'm not sure if this can be extrapolated to spinal cord co...

Would you consider placing a stent in this patent graft to minimize closure of the graft after SBRT?

Should elective mediastinal irradiation still be avoided? For example, if you have a T2 RLL lesion, and let's say, a positive AP window node, do you n...

Is there any concern about hemorrhage from treatment effect on tumor? Would SABR worsen the chance of fatal hemorrhage/hemoptysis and if so, would you...

Should mutations other then EGFR and ALK be routinely tested for? Should next generation sequencing be routinely done?

In the case where there is a PET avid subpleural nodule in the exact same location as needle biopsy 3 months prior, is this considered a chest wall me...

For small overall volumes (e.g. 0.5cm solid component, 1cm total lesion size when including GGO), I imagine treating the entirety of the abnormality i...

Do you define it as whole lungs (inc. tumor) or whole lungs minus GTV, CTV,  ITV, or PTV?

We've seen quite a few patients present with NSCLC with a single brain metastasis and a good performance status. Would you advocate for an aggressive ...

ASTRO 2014's lung session presented data from RTOG 0236, showing a 20% intralobar failure/recurrence despite only 7% local failure. How does one recon...

RTOG 0915 allows either technique, but I've heard people say that IMRT is not "technically" SBRT. Is there is a benefit to the non-coplanar 3D techniq...

The patient underwent lobectomy and nodal staging for a presumed non-small cell lung cancer.

Dose/Fractionation? Concurrent v. sequential chemo? What literature do you use to backup PORT for a positive margin?

In SBRT, it has been said that Pencil Beam dose calculation algorithm can overestimate the target dose and understimate the normal tiss...

I've read about patients who were treated with concurrent bevacizumab-RT who developed lethal tracheoesophageal fistulas. How long would you have to w...

What dose/fractionation is appropriate and does it differ between histology?

What are the primary data that drove organ at risk and conformality dose constraints?  

Is a biopsy needed? Do you consider treatment palliative or curative?

I've found that very few patients have a regular breathing cycle, which makes respiratory gating very difficult. Any other solutions?


Papers discussed in this category


J Thorac Oncol, 2007 Jul

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2014-03

Int J Radiat Oncol Biol Phys, 2002 Mar 15

The Lancet. Oncology, 2015-02

Radiat Oncol, 2007 Jun 7

International journal of radiation oncology, biology, physics, 2013-09-01

JAMA, 2010-03-17

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2009-07

Clinical oncology (Royal College of Radiologists (Great Britain)), 2007-09

Radiation oncology (London, England), 2014-01-03

Int. J. Radiat. Oncol. Biol. Phys., 2010-03-15

The New England journal of medicine, 2012-06-14

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-10-20

International journal of radiation oncology, biology, physics, 2012-08-01

International journal of radiation oncology, biology, physics, 2014-07-01

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2009-06

J Thorac Oncol, 2011 Dec

International journal of radiation oncology, biology, physics, 2013-08-01

Radiother Oncol, 2011 Nov

International journal of radiation oncology, biology, physics, 2010-03-01

Cancer, 2006-05-01

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2006-11

Journal of thoracic disease, 2011-03

Lancet Oncol., 2006-09-01

The Journal of thoracic and cardiovascular surgery, 2013-03

Int. J. Radiat. Oncol. Biol. Phys., 2010-06-01

Medical physics, 2013-09

International journal of radiation oncology, biology, physics, 2010-06-01

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2009-08

International journal of radiation oncology, biology, physics, 2007-10-01

Int J Radiat Oncol Biol Phys, 2000 Nov 1

N Engl J Med, 2007 Aug 16

J Clin Oncol, 1999 Jul

Lancet, 2015 Jan 3

International journal of radiation oncology, biology, physics, 2011-11-01

Int. J. Radiat. Oncol. Biol. Phys., 2006-09-01

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2017-12

Lancet Oncol., 2017-05-01

The New England journal of medicine, 1999-08-12

BMC Cancer, 2015-08-15

Journal of cancer research and therapeutics, 2012

International journal of radiation oncology, biology, physics, 2012-05-01

Neurosurgery, 2013-10

Practical radiation oncology, 2015

J. Neurosurg., 2005-01-01

J Korean Neurosurg Soc, 2011-08-01

Radiat Oncol, 2014-07-08

BMC Cancer, 2015-03-04

Acta Neurochir (Wien), 2013-01-01

International journal of radiation oncology, biology, physics, 2010-03-01

American journal of clinical oncology, 2015-08

Lung Cancer, 2009-11-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001-01-01

Journal of the National Cancer Institute, 2011-10-05

International journal of radiation oncology, biology, physics, 2006-07-15

International journal of radiation oncology, biology, physics, 2010-06-01

J Natl Cancer Inst, 1991 Mar 20

International journal of radiation oncology, biology, physics, 2002-10-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002-08-15

Journal of the National Cancer Institute, 2016-09

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-01

Cancer, 1998 Mar 15

International journal of radiation oncology, biology, physics, 2012-11-01

International journal of radiation oncology, biology, physics, 2017-03-15

International journal of radiation oncology, biology, physics, 2015-11-15

Radiother Oncol, 2013 Aug

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2016-10

International journal of radiation oncology, biology, physics, 2016-12-01

Practical radiation oncology, 2018

Radiation oncology (London, England), 2013-01-03

N Engl J Med, 2014 Sep 27

International journal of radiation oncology, biology, physics, 2014-12-01

International journal of radiation oncology, biology, physics, 2014-04-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-07-01

International journal of radiation oncology, biology, physics, 2012-06-01

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015-01

Lancet, 1998 Jul 25

Int. J. Radiat. Oncol. Biol. Phys., 1999-08-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-03-10

International journal of radiation oncology, biology, physics, 2015-06-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-01-10

J Natl Cancer Inst, 2014 Aug

Int. J. Radiat. Oncol. Biol. Phys., 2014-04-01

Radiat Oncol, 2015 May 27

International journal of radiation oncology, biology, physics, 2016-06-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-04-01

The New England journal of medicine, 2016-11-10

The New England journal of medicine, 2018-01-11

N. Engl. J. Med.,

International journal of radiation oncology, biology, physics, 2005-09-01

Am. J. Clin. Oncol., 2007-06-01

Int J Radiat Oncol Biol Phys, 2008 Oct 1

The New England journal of medicine, 2015-10-22

International journal of radiation oncology, biology, physics, 2015-11-01

Eur. J. Nucl. Med. Mol. Imaging, 2014-06-01

The Lancet. Oncology, 2015-06

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-11-01

Semin Radiat Oncol, 2015 Oct

Journal of applied clinical medical physics, 2010-08-19

Technology in cancer research & treatment, 2016-02

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007-07-20

J. Clin. Oncol., 2006-03-01

N. Engl. J. Med., 1987-04-09

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997-08

J Thorac Cardiovasc Surg, 2011 Mar

J. Clin. Oncol., 2008-07-20

Chest, 2007 Sep

Clinical lung cancer, 2016-11

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-04-01

Practical radiation oncology, 2013

Lancet Oncol., 2014 May 13

The Lancet. Oncology, 2015-08

N Engl J Med, 2014 Mar 27

N Engl J Med, 2013 Jun 20

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-12-01

International journal of radiation oncology, biology, physics, 2010-12-01

Frontiers in oncology, 2014

Radiother Oncol, 2013 Oct

International journal of radiation oncology, biology, physics, 2016-09-01

Radiother Oncol, 2012 Mar

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2011-06

International journal of radiation oncology, biology, physics, 2015-03-15

Int. J. Radiat. Oncol. Biol. Phys., 2008-11-01

Cochrane Database Syst Rev, 2005-04-18

Radiother Oncol, 2002-01-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-11-01

The Lancet. Oncology, 2016-07

International journal of radiation oncology, biology, physics, 2015-09-01

Lung Cancer,

Brachytherapy, 2017

Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi,

Lancet (London, England), 2009-08-01

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013-07

Journal of the National Cancer Institute, 2007-03-21

The Lancet. Oncology, 2015-07

Annals of oncology : official journal of the European Society for Medical Oncology, 2013-09

JCO Precision Oncology, 2017 Sep 29

Sci Rep, 2014 Sep 09

Medicine (Baltimore),

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-10-01

Radiation oncology (London, England), 2015-02-18

JAMA oncology, 2015-11

Rev Mal Respir, 2007-05-01

The Annals of thoracic surgery, 1995-12

Cancer Treat. Rev., 2016-04-01

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015-01

Clin. Cancer Res., 2015-04-15

Lancet (London, England), 2016-04-09

International journal of radiation oncology, biology, physics, 2016-06-01

Radiat Oncol, 2011-12-21

The Lancet. Oncology, 2016-12

Eur. J. Cancer, 2016-02-01

Lancet Oncol., 2014-10-01

J Thorac Oncol, 2016-07-01

The British journal of radiology, 2016

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007-01-20

Cancer, 1981-11-01

N. Engl. J. Med., 1999-01-28

BMJ Open, 2016-01-20

Radiat Oncol, 2016-09-21

Lancet Oncol., 2011-08-01

Clin Lung Cancer, 2018 Nov

International journal of radiation oncology, biology, physics, 2007-05-01

Cancer, 2014-07-01

International journal of radiation oncology, biology, physics, 2014-03-15

Clinical lung cancer, 2016-09

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005-09-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007-05-01

Medical and pediatric oncology, 1990

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1986-01

N Engl J Med, 2017 Nov 16

The Journal of thoracic and cardiovascular surgery, 2008-03

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-08-10

J Thorac Oncol, 2012-04-01

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015-11

Clin Lung Cancer, 2017-07-01

Chest, 2013-11

Annals of oncology : official journal of the European Society for Medical Oncology, 2013-01

Immunotherapy, 2016-10

International journal of radiation oncology, biology, physics, 2011-09-01

J Thorac Oncol,

Clin. Cancer Res., 2015 May 27

Lancet (London, England), 2017-01-21

The New England journal of medicine, 2018-06-14

The Lancet. Respiratory medicine, 2019-05

Ann. Oncol.,

J Thorac Oncol, 2017-02-01

JAMA oncology, 2017-08-01

Clinical lung cancer, 2015-03

European journal of cancer (Oxford, England : 1990), 2007-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003-07-15

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012-11

Lancet, 2014-09-20

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-05-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-05-01

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2017-02

Int. J. Radiat. Oncol. Biol. Phys., 2006-02-01

International journal of radiation oncology, biology, physics, 2009-02-01

The New England journal of medicine, 2018-05-31

Clin Lung Cancer, 2011-11-01

Chest, 2002-04

Cancer, 2013-09-15

International journal of radiation oncology, biology, physics, 2014-05-01

International journal of radiation oncology, biology, physics, 2012-01-01

International journal of radiation oncology, biology, physics, 2011-10-01

International journal of radiation oncology, biology, physics, 2009-04-01

International journal of radiation oncology, biology, physics, 2016-08-01

Hematology/oncology clinics of North America, 2006-02

Radiother Oncol, 2015-10-01

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010-02

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2017-10

International journal of radiation oncology, biology, physics, 2008-09-01

Acta Oncol, 2015 Oct 23

J Med Imaging Radiat Oncol, 2013 Jan 17

J. Clin. Oncol.,

Lancet Oncol., 2017 Jun 20

Lancet, 2011-09-17

Radiation oncology (London, England), 2014-09-19

Int. J. Radiat. Oncol. Biol. Phys.,

Br. J. Cancer, 2006-04-24

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-08-10

The Journal of thoracic and cardiovascular surgery, 2005-04

Radiographics : a review publication of the Radiological Society of North America, Inc, 2014-10

Oncotarget,

Nature, 2017-04-26

Cancer discovery, 2017-12

Cancer discovery, 2016-10

Arthritis & rheumatology (Hoboken, N.J.), 2018-03

Lung cancer (Amsterdam, Netherlands), 1994-03

The Lancet. Oncology, 2016-11

J Thorac Oncol, 2016 Oct 07

J. Natl. Cancer Inst.,

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2017-10

J. Clin. Oncol.,

International journal of radiation oncology, biology, physics, 2014-09-01

The New England journal of medicine, 2017-06-22

Thorac Cardiovasc Surg, 2015 Dec 15

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2009-12

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2014-08

International journal of radiation oncology, biology, physics, 2013-01-01

Science translational medicine, 2013-12-18

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013-02

The New England journal of medicine, 2018-05-31

Annals of surgical oncology, 2002-07

International journal of radiation oncology, biology, physics, 1992

Clin Oncol (R Coll Radiol),

J Thorac Oncol,

International journal of radiation oncology, biology, physics, 2006-07-01

International journal of radiation oncology, biology, physics, 2007-10-01

The New England journal of medicine, 2018-12-13

The New England journal of medicine, 2006-12-14

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-03-01

J Thorac Oncol,

Pulmonary medicine, 2012

Radiat Oncol, 2015 Apr 26

J. Clin. Oncol., 2018 May 22

The New England journal of medicine, 2018-11-22

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013-06

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-03-10

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2017-06

Clin. Cancer Res., 2016 Feb 04

Clin Lung Cancer, 2017 Jul 10

J Thorac Oncol,

Clinical lung cancer, 2018-07

Int. J. Radiat. Oncol. Biol. Phys., 2017 Mar 15

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2016-06

Annals of internal medicine, 2018-01-16

Neuroendocrinology,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-12-10

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014-04

Surgery,

The Annals of thoracic surgery, 2015-12

The Journal of thoracic and cardiovascular surgery, 2016-05

Lancet (London, England), 2014-08-23

International journal of radiation oncology, biology, physics, 2007-02-01

Cancer Discov,

Clin. Cancer Res.,

N. Engl. J. Med.,

Practical radiation oncology, 2018

Br. J. Cancer,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-09-01

International journal of radiation oncology, biology, physics, 2012-05-01

International journal of radiation oncology, biology, physics, 2012-02-01

Journal of radiosurgery and SBRT, 2011

The Lancet. Oncology, 2017-07

International journal of radiation oncology, biology, physics, 2017-06-01

JAMA oncology, 2018-01-11

The Lancet. Oncology, 2015-07

J. Clin. Oncol., 2019 Dec 11

Oncologist, 2015 Sep 09

J Thorac Oncol, 2016 Jul

J Thorac Oncol, 2018 Feb

J. Clin. Oncol., 2018 Jun 15

The Lancet. Oncology, 2015-02

J. Clin. Oncol., 2017 Dec 14

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015-08

Clinical lung cancer, 2015-11

Medicine (Baltimore),

Eur Radiol, 2016 Mar 04

The New England journal of medicine, 2018-12-06

Medical physics, 2011-11

The Lancet. Respiratory medicine, 2017-11

JAMA Oncol,

Clin Lung Cancer, 2017 Mar

Lung Cancer,

Lancet Oncol., 2008 Jun 24

International journal of radiation oncology, biology, physics, 2013-03-01

Respir. Res., 2018 Apr 24

Clinical cancer research : an official journal of the American Association for Cancer Research, 2016-09-15

J. Clin. Oncol., 2018 Mar 29

J. Clin. Oncol., 2020 Feb 20

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-03-01

Radiother Oncol, 2011 Jun 12

Int. J. Radiat. Oncol. Biol. Phys., 2012 Mar 13

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-01-10

Practical radiation oncology, 2014

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015-04

Journal of oncology, 2018

Clin. Cancer Res., 2017 Oct 24

JAMA oncology, 2017-05-01

Infect Dis Ther, 2018 Feb 01

Int. J. Radiat. Oncol. Biol. Phys.,

Int. J. Radiat. Oncol. Biol. Phys., 2008 Jan 30

Thorac Surg Clin,

International journal of radiation oncology, biology, physics, 2013-04-01

N. Engl. J. Med.,

PLoS ONE, 2015 Nov 24

Semin Radiat Oncol, 2004-01-01

Practical radiation oncology, 2017

International journal of radiation oncology, biology, physics, 1994-06-15

International journal of radiation oncology, biology, physics, 2010-12-01

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010-06

JAMA oncology, 2019-05-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-11-01

International journal of radiation oncology, biology, physics, 2015-07-01

Advances in radiation oncology, 2017

International journal of radiation oncology, biology, physics, 2015-11-15

International journal of radiation oncology, biology, physics, 2016-06-01

J. Clin. Oncol., 2017 Oct 02

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-05-20

Radiology,

J Thorac Oncol, 2018 Jul 26

J. Clin. Oncol., 2015 Nov 02

Radiographics : a review publication of the Radiological Society of North America, Inc, 2004

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-03

The Lancet. Oncology, 2009-05

JAMA oncology, 2019-07-01

Future Oncol, 2019 Apr 25

N. Engl. J. Med., 2017 Jun 04

Clinical cancer research : an official journal of the American Association for Cancer Research, 2017-04-15

The New England journal of medicine, 2005-06-23

N. Engl. J. Med.,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-01-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-06-20

Lancet, 2019 Apr 11

J Thorac Oncol, 2019 Jan 18

J. Thorac. Cardiovasc. Surg.,

Clinical cancer research : an official journal of the American Association for Cancer Research, 2019-08-01

Nat Commun, 2019 Mar 27

JAMA Oncol, 2019 Jul 11

JAMA Oncol, 2019 Jul 11

Cancer Res., 2017 Feb 15

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2018-05

The Annals of thoracic surgery, 2019-08

Eur. Respir. J., 2017 Jun 01

Clin. Cancer Res., 2018 Oct 08

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2019-02

Lancet, 2019 Oct 04

International journal of radiation oncology, biology, physics, 2018-03-15

J Thorac Oncol, 2019 Feb 16

Cancer discovery, 2017-04

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-06-01

International journal of radiation oncology, biology, physics, 2018-08-01

Int. J. Radiat. Oncol. Biol. Phys., 2016 Jul 15

Eur. Respir. J., 2018 Jan 04

Practical radiation oncology, 2018

Crit. Care Med.,

Journal of radiosurgery and SBRT, 2013

Practical radiation oncology, 2018

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2016-08

J Thorac Dis,

Clinical lung cancer, 2013-03

J. Clin. Oncol., 2012 Apr 02

Semin. Cancer Biol., 2019 Jul 19

J Natl Compr Canc Netw,

The Journal of molecular diagnostics : JMD, 2018-03

Ann. Oncol.,

Lancet Oncol., 2012 May 22

Science (New York, N.Y.), 2015-04-03

Seminars in oncology, 2007-02

JAMA, 2014-05-21

Annals of oncology : official journal of the European Society for Medical Oncology, 2019-08-01

Cancer, 2005-04-15

Cancer, 2017-11-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-08-20

Lancet (London, England), 2019-05-04

N. Engl. J. Med., 2019 Sep 28

Clin. Cancer Res., 2019 Aug 15

Ann. Oncol.,

International journal of radiation oncology, biology, physics, 2016-03-15

Technol. Cancer Res. Treat.,

Cancer, 2011-11-01

Case reports in oncology, 2017

BMC Cancer, 2015 Oct 15

J Thorac Surg,

Lancet Oncol., 2017 Sep 25

Int. J. Radiat. Oncol. Biol. Phys., 2015 Apr 22

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2014-03

Radiother Oncol, 2013 May 03

J Thorac Oncol, 2019 Nov 09

The New England journal of medicine, 2011-08-04

N. Engl. J. Med., 2020 Jan 29

Medical physics, 2014-03

The New England journal of medicine, 2014-11-13

Lancet Oncol., 2017 Sep 11

JAMA Netw Open, 2020 Feb 05

The New England journal of medicine, 1990-10-04

J. Clin. Oncol., 2019 Dec 16